Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14721001 | 0.80 | DGAT1 (0.44) | DGAT1PARP1EPHX1RCE1KIF11 | |
| SCHEMBL14720245 | 0.76 | DGAT1 (0.53) | DGAT1CES2CES1PARP1 | |
| SCHEMBL7464198 | 0.75 | CES2 (0.62) | CES2CES1PARP1EPHX1 | |
| SCHEMBL1317647 | 0.70 | DGAT1 (0.55) | DGAT1PARP1KIF11 | |
| SCHEMBL2144930 | 0.70 | GABRA1 (0.38) | DGAT1RCE1 | |
| SCHEMBL7480529 | 0.69 | GRM8 (0.34) | CES2CES1 | |
| SCHEMBL28915928 | 0.68 | AKR1C3 (0.40) | DGAT1 | |
| SCHEMBL18099486 | 0.66 | DGAT1 (0.31) | DGAT1RCE1 | |
| SCHEMBL2426635 | 0.66 | PDE2A (0.34) | DGAT1 | |
| SCHEMBL21753688 | 0.66 | TSHR (0.40) | DGAT1PARP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744333-B1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| US-9084794-B2 | Fatty acid synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property (No2) Limite (GB) | 2014-07-10 | — | — | US | disclosed |
| EP-2744333-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013028447-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS2, FADS1 | DGAT1 93/4885CES2 384/4885CES1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.